Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
ConditionNon-small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital
About this trial
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Eligibility criteria
Qualifiers
18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
Uncommon EGFR Mutant Advanced NSCLC
Disqualifiers
Patients with contraindication of chemotherapy
Pregnant or breast feeding women
Trial design
Treatments tested in this trial
- Third-generation EGFR-TKI
- EGFR-TKI
Treatment groups
800 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov